AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00090909
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00090909
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02021214
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01945944
Drug: Placebo (0.9% saline)
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3mL of normal saline given via nebulizer every 6hrs
Trial: NCT00526318
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00526318
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00526318
Drug: dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00526318
Drug: etoposide phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00526318
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00526318
Drug: isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00526318
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00526318
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00526318
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00526318
Drug: vindesine
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02154438
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketamine 0.5mg/kg loading followed by 0.5mg/kg/h infusion during operation
Trial: NCT03912740
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in the dexmedetomidine-remifentanil group will receive an infusion of 0.6 mcg/kg in half an hour followed by an infusion of 0.6 mcg/kg/hour.
Trial: NCT03912740
Drug: sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the remifentanil group will receive an infusion of 0.9% sodium chloride instead of dexmedetomidine (identical infusion rate)
Trial: NCT00807365
Drug: GHRH
RxNorm normalized name: GHRH
DrugBank: Tesamorelin (DB08869)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 Post Meridian (PM), 1:00 Ante Meridian (AM), 3:00 AM, \& 5:00 AM for 6 months.
Trial: NCT00039390
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01956253
Drug: Neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 240 mg orally once daily
Trial: NCT00008359
Drug: caspofungin acetate
RxNorm normalized name: Caspofungin Acetate
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00008359
Drug: liposomal amphotericin B
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00508911
Drug: COC
RxNorm normalized name: Cocet
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COC containing ethinylestradiol 30 microgram and levonorgestrel 150 microgram will be administered in the morning with a light breakfast.
Trial: NCT00954187
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days
Trial: NCT00954187
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg PO TID
Trial: NCT00490971
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily in dose range of 5 to 20 mg/day for 15 weeks, then until recurrence
Trial: NCT03245151
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension
Trial: NCT03245151
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 mg, 3 mg, or 5 mg tablets for oral suspension
Trial: NCT00490971
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Once daily in dose range of 3 to 12 mg/day for 15 weeks, then until recurrence
Trial: NCT04142359
Drug: N-803 alone
RxNorm normalized name: (+/-)-N-methylephedrine
DrugBank: DL-Methylephedrine (DB11278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-803 alone
Trial: NCT02021461
Drug: ESL Banana taste
DrugBank: Banana (DB10505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension with Banana flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
Trial: NCT04303416
Drug: Albumin solution
RxNorm normalized name: darbepoetin alfa in albumin solution
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: plasma exchange with albumin, one per week for one month, then one per month for 5 months
Trial: NCT02204332
Drug: Cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00593450
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: • 0.5 mg (0.05 mL)intravitreal injection
Trial: NCT00593450
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: • 1.25 mg (0.05 mL)intravitreal injection
Trial: NCT04500249
Drug: rescue IA
RxNorm normalized name: magnesium aluminum silicate type Ia
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: in the case of intraoperative pain perception, rescue intravenous analgesia using 50 mcg of fentanyl will be administered by anaesthesiologist
Trial: NCT01526785
Drug: Alglucosidase alfa
RxNorm normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4000 L alglucosidase alfa administered by IV infusion at the same dose and dose regimen used for the patient's routine treatment prior to the study for 52 weeks.
Trial: NCT02789969
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone 15mcg/kg IV
Trial: NCT00369252
Drug: Nimotuzumab (TheraCIM h-R3)
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01628562
Drug: Esmolol
RxNorm normalized name: Esmolol
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esmolol 50 mcg/kg/min
Trial: NCT00847418
Drug: esketamine hydrochloride
RxNorm normalized name: esketamine hydrochloride
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02007720
Drug: Serelaxin
RxNorm normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT02450045
Drug: 0.5% Ropivacaine/0.125% Bupivacaine local anesthetic mixture
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00957177
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300mg pregabalin orally 1 hour before operation
Trial: NCT03127319
Drug: apatinib docetaxel zoledronic
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: apatinib 500 mg qd p.o.docetaxel 60mg/m² iv q3w;zoledronic 4mg iv\>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
Trial: NCT03127319
Drug: docetaxel zoledronic
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 60mg/m² iv q3w;zoledronic 4mg iv\>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
Trial: NCT02898077
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT02898077
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT01638429
Drug: Neomycin
RxNorm normalized name: Neomycin
DrugBank: Neomycin (DB00994)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neomycin: 500mg po bid for 10 days
Trial: NCT01638429
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin: 550mg po tid for 10 days
Trial: NCT02703181
Drug: Epelsiban (GSK557296)
RxNorm normalized name: Epelsiban
DrugBank: Epelsiban (DB11934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to off-white 0.270 inches x 0.700 inches oblong film coated tablet containing 25 mg or 100 mg epelsiban. To be swallowed whole with water, not to be chewed.
Trial: NCT01419535
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mifepristone 50mg tablet by mouth every six hours for nine days.
Trial: NCT01461733
Drug: amiodarone
RxNorm normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: standard dose amiodarone
Trial: NCT02939209
Drug: Hydromorphone Hcl 2Mg Tab
RxNorm normalized name: HYDROMORPHONE HCL 2MG TAB
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given 2 mg hydromorphone (immediate release formulation) in the post anesthetic care unit.
Trial: NCT02240459
Drug: fesoterodine 4mg
RxNorm normalized name: fesoterodine fumarate 4 MG
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning
Trial: NCT02240459
Drug: Oxybutynin
RxNorm normalized name: Oxybutynin
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo
Trial: NCT02240459
Drug: fesoterodine 8mg
RxNorm normalized name: fesoterodine fumarate 8 MG
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2, 4mg fesoterodine capsules taken together in the morning
Trial: NCT00803712
Drug: Cinacalcet
RxNorm normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cinacalcet is a calcimimetic agent, which is synthesized as a hydrochloride salt.
Trial: NCT00803712
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titration of active Vitamin D in accordance with treatment practice guidelines in order to treat Secondary Hyperparathyroidism.
Trial: NCT05178823
Drug: Chlorhexidine mouthwash
RxNorm normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of oral rinses
Trial: NCT04380376
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhalations with low doses of Melphalan for 7-10 consequent days
Trial: NCT02876796
Drug: GS-0976
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsule(s) administered orally
Trial: NCT04052607
Drug: LH Suppression
RxNorm normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulation protocols
Trial: NCT02360774
Drug: Canagliflozin
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
Trial: NCT01757197
Drug: Toclizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 mg/kg IV, once every 1-2 weeks. The maximum dose per infusion should not exceed 800 mg.
Trial: NCT01082679
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily for 12 months
Trial: NCT01082679
Drug: buprenorphine (Suboxone)
RxNorm normalized name: buprenorphine / naloxone Sublingual Film [Suboxone]
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: daily for 12 months
Trial: NCT02415192
Drug: Levacalm
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02415192
Drug: Valsartan/amlodipine
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03161041
Drug: bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
Trial: NCT01194375
Drug: High Strength IDP-107
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day for 16 weeks
Trial: NCT00762762
Drug: Triclosan/copolymer/fluoride
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush whole mouth 2x/day for 12 months with triclosan/copolymer/fluoride toothpaste. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
Trial: NCT00762762
Drug: Fluoride
RxNorm normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Swished around whole mouth twice daily for 12 months. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
Trial: NCT00027547
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00027547
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00027547
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00027547
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00678015
Drug: Nordihydroguaiaretic Acid (NDGA)
RxNorm normalized name: nordihydroguaiaretic acid, (+/-)-
DrugBank: Masoprocol (DB00179)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NDGA 2000mg daily
Trial: NCT02408731
Drug: PMZ-2010 (Centhaquin)
RxNorm normalized name: Centhaquine
DrugBank: Centhaquine (DB16122)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.
Trial: NCT00448214
Drug: YM150
RxNorm normalized name: Yohimbine
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00448214
Drug: warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00075452
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00075452
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03981146
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 60 Minute IV Infusion
Trial: NCT01239394
Drug: ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly infusion for 8 weeks
Trial: NCT01747096
Drug: 68-Ga-DOTANOC
RxNorm normalized name: 68-ga-dotanoc
DrugBank: Dotatoc gallium Ga-68 (DB18190)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00630799
Drug: leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 mg i.m.
Trial: NCT00334464
Drug: Standard of care or genotyping dosing of warfarin dosing
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03450759
Drug: AZD9977 ER capsule (fastvrate)
RxNorm normalized name: Castor Oil Capsules
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized subjects will receive single oral dose of AZD9977 ER capsule (fast rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
Trial: NCT01223404
Drug: Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule
Trial: NCT00363688
Drug: Penicillin test and challenge
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01223404
Drug: Mecamylamine
RxNorm normalized name: Mecamylamine
DrugBank: Mecamylamine (DB00657)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine
Trial: NCT02060370
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting dose: 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks.
Trial: NCT00526448
Drug: ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000 mg/day
Trial: NCT00526448
Drug: ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000-1200 mg/day
Trial: NCT00526448
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a 180 mcg/week
Trial: NCT00526448
Drug: epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: epoetin beta 450 UI/week
Trial: NCT01697800
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00954122
Drug: Quetiapine XR (Seroquel XR)
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, oral, once daily
Trial: NCT00281515
Drug: Lonafarnib
RxNorm normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg/twice a day during chemotherapie,in maintenance phase 200 mg twice a day
Trial: NCT01170975
Drug: Tesetaxel 10 mg with and then without food
DrugBank: Tesetaxel (DB12019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Period 1: Tesetaxel 10 mg in the fed state; Treatment Period 2: Tesetaxel 10 mg in the fasted state
Trial: NCT02467361
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 3 mg/kg is administered intravenously over 90 minutes every 21 days for a total of 4 doses.
Trial: NCT02467361
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes every 14 days.
Trial: NCT02467361
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every 21 days.
Trial: NCT02049736
Drug: Telbivudine
RxNorm normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01170975
Drug: Tesetaxel 10 mg without and then with food
DrugBank: Tesetaxel (DB12019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Period 1: Tesetaxel 10 mg in the fasted state; Treatment Period 2: Tesetaxel 10 mg in the fed state
Trial: NCT01511783
Drug: E2609
RxNorm normalized name: Elenbecestat
DrugBank: Elenbecestat (DB15391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.